RESUMEN
To evaluate a newly developed immunochromatographic test (the MySet test) for the detection of Chlamydophila pneumoniae-specific immunoglobulin M antibodies, the results obtained by the MySet test were compared with those obtained by two serological tests. The sensitivity and specificity of the MySet test were 100% and 92.9%, respectively. The MySet test is rapid and simple to use and is thought to be a useful tool for the selection of appropriate antibiotic therapy.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Infecciones por Chlamydophila/diagnóstico , Chlamydophila pneumoniae/inmunología , Inmunoensayo/métodos , Inmunoglobulina M/sangre , Neumonía Bacteriana/diagnóstico , Adolescente , Adulto , Niño , Preescolar , Infecciones por Chlamydophila/inmunología , Infecciones por Chlamydophila/microbiología , Infecciones Comunitarias Adquiridas/diagnóstico , Infecciones Comunitarias Adquiridas/inmunología , Femenino , Humanos , Inmunoensayo/instrumentación , Masculino , Persona de Mediana Edad , Neumonía Bacteriana/inmunología , Sensibilidad y EspecificidadRESUMEN
BACKGROUND AND OBJECTIVE: To evaluate an enzyme immunoassay (EIA) (AniLab C. pneumoniae) for detecting anti-Chlamydophila pneumoniae-specific IgM antibody, by comparing it with an ELISA, Hitazyme C. pneumoniae, and a micro-immunofluorescence (MIF) test. METHODS: Antibodies in sera from three groups of patients were measured: eight serum samples collected serially from a patient with acute C. pneumoniae pneumonia, 34 serum samples with Hitazyme-ELISA false-positive results, and 137 serum samples from patients with community-acquired pneumonia. RESULTS: The IgM antibody titre in the patient with acute C. pneumoniae pneumonia showed almost identical variation with the EIA, ELISA and MIF tests. Among the 34 samples found to be false-positive for IgM with ELISA, EIA revealed no positive cases. When a true positive case was defined as one for which a positive reaction was obtained with at least two tests, the sensitivities of the EIA, ELISA and MIF tests were 97.1%, 100% and 74.3%, with specificities of 100%, 37.3% and 100%, respectively. CONCLUSIONS: EIA was highly sensitive and specific as compared with the MIF test, and the ELISA test showed the lowest specificity. Consequently, the AniLab-EIA, rather than the Hitazyme-ELISA, is recommended as the routine method for accurately diagnosing acute C. pneumoniae infection.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Infecciones por Chlamydophila/diagnóstico , Chlamydophila pneumoniae/inmunología , Inmunoglobulina M/sangre , Pruebas Serológicas/métodos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Infecciones por Chlamydophila/sangre , Infecciones por Chlamydophila/inmunología , Ensayo de Inmunoadsorción Enzimática , Reacciones Falso Positivas , Femenino , Técnica del Anticuerpo Fluorescente Indirecta , Humanos , Técnicas para Inmunoenzimas , Pulmón/microbiología , Masculino , Persona de Mediana Edad , Sensibilidad y EspecificidadRESUMEN
We compared reactivity between Chlamydia serovar antigens and sera from 18 patients using immunoblotting (IB) and enzyme-linked immunosorbent assay (ELISA). The antigens used were Chlamydia trachomatis serovar L2, D, E, and C organisms for IB and synthetic peptides derived from C, E, G, and L2-VDIV genes for ELISA. Eleven of 12 sera collected from Chlamydia antigen-positive women with cervicitis strongly reacted with C. trachomatis serovar E, as did one serum with serovar C in immunoblotting profiles. ELISA coated individually with peptides E and C strongly reacted with the sera of 6 different patients. The IB result between serovar L2, D, E, and C and sera from the 6 other women patients showed reactivity at E > or = D > or = L2 > or = C. ELISA using a synthetic peptide mixture including C, E, G and L2 peptides gave positive results for all 18 sera. These results indicate that IB sensitivity differes with the C. trachomatis serovar antigen used and that certain cases may produce inconsistent results between IB and ELISA. Results of ELISA and IB are thus not always consistent, indicating that different synthetic peptides should be used in ELISA for detecting of low-level C. trachomatis antibodies.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Chlamydia trachomatis/inmunología , Immunoblotting , Antígenos Bacterianos/inmunología , Ensayo de Inmunoadsorción Enzimática , Femenino , HumanosRESUMEN
To find a new marker for sero-diagnosis of Chlamydia trachomatis infection, Western blot (WB) method was performed by using C. trachomatis infected HeLa229 cell extract (L2-ext) as antigen. Two series of sera of patients with pneumonia or cervicitis (4 sera each) were used for investigation and analysis of a band which fades earlier than others depending on weeks or antibody levels after therapeutic treatment. A 17 KDa band was found which tended to fade gradually, but did not completely disappear within the period of investigation. The band was also detected in sera of patients with cervicitis diagnosed by detection of C. trachomatis organisms (IDEIA-PCE Chlamydia (IDEIA) or Clearview test were positive at first visit to the clinic). Ten anti-C. pneumoniae antibody positive sera and five anti-Mycoplasma pneumoniae antibody positive sera were also tested as controls. The result was that a 17 KDa band was detected in 20 of 25 sera (80%) with IDEIA positive. 18 of 33 patients (54.5%) with Clearview positive-, and 12 of 16 (75%) sera with both tests positive. No band was found in the control sera. The frequency of antibody against 17 KDa antigen was almost completely identical with that obtained by microimmunofluorescence test and Peptide-Chlamydia-IgG test. These results show that a 17 KDa band may be used as a marker for detection of C. trachomatis antibody by the WB method. The antigen could be precipitated with salting out from the L2-ext with 60% saturation of ammonium sulfate of Hofmeister's method and it was digested with proteinase K. From the result of the amino acid sequence analysis, it was found that 17 KDa protein is the human nucleoside diphosphate kinase B.